Featured Research

from universities, journals, and other organizations

Anti-androgen therapy for triple-negative breast cancer may benefit lower-androgen tumors

Date:
June 23, 2014
Source:
University of Colorado Denver
Summary:
Even triple negative breast cancers expressing very low levels of androgen receptor may benefit from anti-androgen therapy, researchers report. "This line of work is starting to change our thinking about who and when -- the timing and patient selection for anti-androgen receptor therapy in triple-negative breast cancer," says the study's first author.

Triple-negative breast cancers do not benefit from the targeted therapies that have greatly improved the survival of patients with other subtypes of breast cancer. But recent work shows that while these cancers lack estrogen receptors, progesterone receptors, and aren't driven by the gene HER2, up to a third of these tumors express the androgen receptor -- clinical trials are underway to inhibit the androgen receptor in these tumors in much the same way that the drug Tamoxifen inhibits estrogen receptor in estrogen-receptor-positive breast cancers. A new University of Colorado Cancer Center study being presented today at the Endocrine Society Annual Meeting shows that even triple negative breast cancers expressing very low levels of androgen receptor may benefit from this therapy.

"This line of work is starting to change our thinking about who and when -- the timing and patient selection for anti-androgen receptor therapy in triple-negative breast cancer," says Valerie Barton, the study's first author and PhD candidate in the lab of CU Cancer Center investigator Jennifer Richer, PhD.

Triple negative breast cancers were recently divided into further subtypes including a subtype with high androgen receptor expression (Lehmann, JCI 2011). However, other subtypes also express the androgen receptor. How would these different subtypes respond to anti-androgen receptor therapy? To find out, Barton and colleagues treated cell lines with the drug enzalutamide and with shRNAs designed to knock down androgen receptor levels. Interestingly, the drug enzalutamide is in wide use for prostate cancer, which tends to be driven by and dependent on androgen receptor.

Results showed that not only does anti-androgen receptor therapy reduce the ability of androgen-receptor-expressing triple-negative breast cancers to proliferate, migrate and invade, but for these cells, androgen receptor seems essential to survival. When Barton and colleagues blocked androgen receptor in these cells, the cells died.

But it was not only the high androgen-receptor-expressing cells that were affected.

"The study showed that androgen receptor has important roles in other subtypes of triple negative breast cancer as well," Barton says.

Across multiple triple-negative breast cancer subtypes, inhibiting the androgen receptor greatly increased apoptosis (programmed cell death), inhibited growth and increased necrosis by 60 percent in animal models.

"We're still early in the study of androgen receptor in breast cancer and already scientists are divvying up the disease to say, for example, that only the high AR expressing subtype should be treated with anti-androgen receptor therapies," Barton says. "But what we show is that even triple negative breast cancers with lower androgen receptor expression critically depend on the androgen receptor and may benefit from anti-androgen receptor therapy. Our results suggest that anti-androgen receptor therapy may benefit a larger percentage of triple negative breast cancers than previously thought."


Story Source:

The above story is based on materials provided by University of Colorado Denver. The original article was written by Garth Sundem. Note: Materials may be edited for content and length.


Cite This Page:

University of Colorado Denver. "Anti-androgen therapy for triple-negative breast cancer may benefit lower-androgen tumors." ScienceDaily. ScienceDaily, 23 June 2014. <www.sciencedaily.com/releases/2014/06/140623121006.htm>.
University of Colorado Denver. (2014, June 23). Anti-androgen therapy for triple-negative breast cancer may benefit lower-androgen tumors. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2014/06/140623121006.htm
University of Colorado Denver. "Anti-androgen therapy for triple-negative breast cancer may benefit lower-androgen tumors." ScienceDaily. www.sciencedaily.com/releases/2014/06/140623121006.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
CDC Calls for New Ebola Safety Guidelines

CDC Calls for New Ebola Safety Guidelines

AP (Oct. 20, 2014) Centers for Disease Control and Prevention Director Dr. Tom Frieden laid out new guidelines for health care workers when dealing with the deadly Ebola virus including new precautions when taking off personal protective equipment. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins